The number needed to treat in pairwise and network meta-analysis and its graphical representation

Veroniki, Areti Angeliki; Bender, Ralf; Glasziou, Paul; Straus, Sharon E.; Tricco, Andrea C.

Published in:
Journal of Clinical Epidemiology

DOI:
[10.1016/j.jclinepi.2019.03.007](https://doi.org/10.1016/j.jclinepi.2019.03.007)

Licence:
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

Recommended citation(APA):
Veroniki, A. A., Bender, R., Glasziou, P., Straus, S. E., & Tricco, A. C. (2019). The number needed to treat in pairwise and network meta-analysis and its graphical representation. *Journal of Clinical Epidemiology*, 111, 11-22. <https://doi.org/10.1016/j.jclinepi.2019.03.007>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

Accepted Manuscript

The number needed to treat in pairwise and network meta-analysis and its graphical representation

Areti Angeliki Veroniki, Ralf Bender, Paul Glasziou, Sharon E. Straus, Andrea C. Tricco

PII: S0895-4356(18)30596-1

DOI: <https://doi.org/10.1016/j.jclinepi.2019.03.007>

Reference: JCE 9845

To appear in: *Journal of Clinical Epidemiology*

Received Date: 3 July 2018

Revised Date: 30 November 2018

Accepted Date: 6 March 2019

Please cite this article as: Veroniki AA, Bender R, Glasziou P, Straus SE, Tricco AC, The number needed to treat in pairwise and network meta-analysis and its graphical representation, *Journal of Clinical Epidemiology* (2019), doi: <https://doi.org/10.1016/j.jclinepi.2019.03.007>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The number needed to treat in pairwise and network meta-analysis and its graphical representation

Areti Angeliki Veroniki^{1,2,3*}; Email: averonik@cc.uoi.gr

Ralf Bender⁴; Email: ralf.bender@iqwig.de

Paul Glasziou⁵; Email: pglaszio@bond.edu.au

Sharon E. Straus^{1,6}; Email: sharon.straus@utoronto.ca

Andrea C. Tricco^{1,7}; Email: triccoa@smh.ca

¹ Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, East Building, Toronto, Ontario, M5B 1T8;

² Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece

³ Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College, London W12 0NN, UK

⁴ Department of Medical Biometry, Institute for Quality and Efficiency in Health Care (IQWiG), Im Mediapark 8, 50670 Cologne, Germany

⁵ Centre for Research on Evidence Based Practice, Bond University, Gold Coast, Australia

⁶ Department of Geriatric Medicine, University of Toronto, Toronto, Ontario;

⁷ Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, 155 College Street, 6th floor, Toronto, Ontario, M5T 3M7, Canada

*Corresponding Author:

Areti Angeliki Veroniki, MSc, PhD

Department of Primary Education, School of Education, University of Ioannina, Ioannina,
Greece

Telephone: 0030 26510 05712

Email: averonik@cc.uoi.gr

Fax: 0030 26510 05854

Declaration of Interest

Drs. Tricco A.C. and Straus S.E. are on the editorial board of the Journal of Clinical Epidemiology, but were not involved with the peer review process or decision for publication and not involved in any way in the journal management of this manuscript. The other authors have nothing to declare.

Abstract

Objective: To present ways to graphically represent a number needed to treat (NNT) in (network) meta-analysis (NMA).

Study Design and Setting: A barrier to using NNT in NMA when an odds ratio (OR) or risk ratio (RR) is used is the determination of a single control event rate (*CER*). We discuss approaches to calculate a *CER*, and illustrate six graphical methods for NNT from NMA. We illustrate the graphical approaches using a NMA of cognitive enhancers for Alzheimer's dementia.

Results: The NNT calculation using a relative effect measure, such as OR and RR, requires a *CER* value, but different *CER*s, including mean *CER* across studies, pooled *CER* in meta-analysis, and expert opinion-based *CER* may result in different NNTs. A NNT from NMA can be presented in a bar plot, Cates plot or forest plot for a single outcome, and a bubble plot, scatterplot or rank-heat plot for ≥ 2 outcomes. Each plot is associated with different properties and can serve different needs.

Conclusion: Caution is needed in NNT interpretation, as considerations such as selection of effect size and *CER*, and *CER* assumption across multiple comparisons, may impact NNT and decision-making. The proposed graphs are helpful to interpret NNTs calculated from (network) meta-analyses.

Keywords: multiple treatment meta-analysis; multiple outcomes; number needed to harm; rank-heat plot; graphical displays; presentation results

Word Count: #200 (abstract), #5,265 (main text), 6 figures, 1 supplementary file

What is New?

Key Findings:

- The number needed to treat (NNT) is an absolute measure of effect used to communicate the effectiveness or safety of an intervention and is frequently used in the meta-analytical literature.

What this adds to what is known:

- Different considerations of calculating a NNT in both pairwise and network meta-analysis (NMA), including effect size and assumptions for the control event rate across multiple comparisons, may impact NNT results. We present potential ways of calculating NNT in (network) meta-analysis, such as mean control event rate (*CER*) across studies, pooled *CER* in meta-analysis, expert opinion-based *CER*, and range of possible *CERs*.

What is the implication?

- The graphical representation of NNTs from NMA is crucial to ease interpretation of results. We present six graphical approaches for NNT from NMA and discuss their properties. We suggest the NNT graphical representation in a bar plot, Cates plot or forest plot for a single outcome, and in a bubble plot, scatterplot or rank-heat plot for at least two outcomes.

What should change now?

- Different plots can be used for different needs. For example, if uncertainty around NNT should be considered in decision-making, then a bar plot or a forest plot can be used. When multiple outcomes need to be considered, then a rank-heat plot is suggested. For communication purposes the Cates plot is suggested if the corresponding effect estimate is statistically significant and the confidence interval is not too wide.

1. Introduction

The number needed to treat (NNT) is an absolute measure of effect used to communicate the effectiveness or safety of an intervention [1]. The NNT was first introduced to describe the absolute effect of a certain intervention versus a standard treatment or control in randomized clinical trials [2] and then was adopted in systematic reviews and meta-analyses [3]. The NNT provides insight into the clinical relevance of an effect size because it is defined as the average number of patients who need to be treated to prevent one extra person from having a bad outcome compared to another treatment. For positive outcomes, the NNT can be equivalently defined as the number of people that need to be treated to have one person with a good outcome. Similarly, the number needed to harm (NNH) indicates how many people need to be treated in order for one patient to have a particular adverse effect. To avoid the unfavorable NNH term, Altman [4] suggested the terms ‘number needed to treat for an additional beneficial outcome’ (NNTB) and ‘number needed to treat for an additional harmful outcome’ (NNTH), respectively, instead of using NNT and NNH to show direction of effect. In this paper, we use the terms NNTB and NNTH.

The NNTB and NNTH are calculated by taking the inverse of the risk difference (RD) [2], yet can also be calculated using other effect measures, such as the odds ratio (OR) and risk ratio (RR) [5]. The higher the NNTB value, the less effective the treatment will be; and, the higher the NNTH, the more safe a treatment is. For example, intervention A with a NNTB of 20 whereby one patient is saved for every 20 patients treated with A is better than a competing intervention B (with a NNTB of 80) that saves one patient for every 80 patients treated with B. The use and interpretation of NNT requires understanding of several factors [1, 6], such as: 1) clinical insight and patient values and circumstances,

as it may depend on how difficult it is to implement the intervention and how accessible and cost-effective the intervention is, 2) follow-up period, as NNTs in studies with different follow-up times are not directly comparable [7], 3) baseline risk of the event, 4) statistical properties of NNT, 5) alternative treatment to which the intervention is being compared, 6) outcome, 7) direction and size of the effect measure, 8) NNTB (and NNTH) scale, and 9) confidence interval (CI) surrounding NNTB or NNTH [4, 8]. CIs for NNTs can be calculated to inform us about the range of NNT values we may expect. However, CIs for the estimated NNTs are usually given for statistically significant results [8], and this is mainly due to a complication of the NNT calculation when dealing with non-significant results (i.e., there is discontinuity when RD is 0).

The NNT measure has been particularly useful in systematic reviews and meta-analyses [3]. However, caution is needed in the NNT calculation as differences in baseline risks, lengths of follow-up, outcome definitions, and clinical settings across the studies included in a meta-analysis can impact the magnitude and direction of NNT [1]. In the meta-analysis context, it is recommended to calculate NNT using an overall treatment effect that remains constant in baseline risk variations. For example, it has been shown that OR and RR effect measures appear to be relatively constant for differences in *CERs* across studies [9]. Caution is also needed when the between-study heterogeneity in the included studies' results is substantial. When the study-specific effect measures vary substantially (e.g., due to notable differences in baseline risks or in patient characteristics or in study-designs), it may not be advisable to combine the study results into a single overall effect estimate or calculate the respective NNT.

Overall, the NNT is a clinically useful measure for expressing binary and survival outcome results [10], and is frequently used in the published literature [11-13]. Several

attempts have also been made to extend NNT for continuous outcomes [14, 15], as well as to graphically represent NNTs [4, 16, 17]. However, knowledge users (such as patients, healthcare providers, and policy-makers) are faced with a multitude of intervention options and the need to compare several treatments for a clinical condition are required to make informed health-care decisions. As such, more complex statistical approaches, such as network meta-analysis (NMA) are required. NMA combines the results of trials that undertake different treatment comparisons [18-20] and is being conducted with increasing frequency in the healthcare literature [21, 22]. The aim of this paper is to present graphical approaches of NNTs from NMA to facilitate interpretation of results.

2. Number needed to treat in pairwise and network meta-analysis

A NNT can be calculated from the overall RD, RR, and OR effect measures using the following formulas:

$$NNT = 1/|RD|$$

$$NNT = \frac{1}{(1 - RR) \cdot CER}$$

$$NNT = \frac{1 - CER + OR \cdot CER}{(1 - OR) \cdot CER \cdot (1 - CER)}$$

where *CER* is the control (or placebo or usual care) event rate, defined as the observed risk of having an event in the control group (ranges between 0 and 1). A barrier to expanding the use of NNT in meta-analysis when an OR or RR is used, is the determination of a single *CER* value, as the *CER* will vary for each study included in the meta-analysis. Below we present potential ways of analyzing *CER* in meta-analysis:

1. The naïve approach, where the sum of events in the control group is divided by the sum of patients in the control group.
2. Median/Mean *CER* across all studies containing the control group
3. Pooled *CER* from a meta-analysis across all studies containing the control group
4. Expert opinion based, for example, on the patient population included across the studies or on local data from the researcher's own patient population
5. A range of possible *CER* values, which can be used to compare potential NNT differences.

Of all approaches, the naïve should be avoided, as it ignores study randomization and between-study variability. To derive a pooled *CER* across studies in a meta-analysis, we may need to use transformations [23]. The *CER* follows a binomial distribution and its variance, which is a function of the mean, reaches a maximum value at $CER = 0.5$. While this works well for *CER* around 0.5, when *CER* is closer to 0 or 1 its variance declines to 0, and hence an inverse-variance meta-analysis assigns a very large weight to these studies [23]. Variance-stabilizing transformations help not only to correct this problem in binomial data, but also to obtain a sampling distribution closer to a normal distribution. Two of the most common variance-stabilizing transformations are the *logit* or *double arcsine* transformations [23]. While the *logit* transformation helps better approximate a normal distribution, the transformed sampling variance can be quite inaccurate. For a *CER* close to 0 or 1 its variance becomes extremely large, while for a *CER* close to 0.5 its variance becomes extremely low [23]. Hence, an inverse-variance meta-analysis assigns small weights to studies with small or large *CERs* and large weights to *CERs* around 0.5, irrespective of the sample size. To improve normalizing and variance-stabilizing the *CER* sampling distribution, Freeman and Tukey [24] suggested the *double arcsine*

transformation. A back-transformation on the original *CER* scale can be performed using the approach suggested by Miller [25]. However, it has been suggested not to use the *double arcsine* transformation for meta-analysis of single proportions due to potential problems with the back-transformation [26]. As alternative, the application of generalized linear mixed models is proposed [26].

Extending the calculation of NNT in NMA, additional considerations to the above should be made. First, the order of treatments when these are compared in a NMA should be presented in a meaningful and consistent way, to facilitate the *CER* choice and the NNT interpretation. A consistent way could be ordering treatments within comparisons referring to active treatment versus placebo/usual care or referring to new pharmacological treatment versus old pharmacological treatment (alternative strategies are needed for non-pharmacological interventions). Let us consider the fictional example of 6 studies comparing treatments A, B, and C, as shown in Appendix 1. If treatment C is newer than treatment B, which is newer than treatment A, then a presentation of the treatment comparisons evaluated in the 6 different studies could be B vs. A, B vs. A, B vs. A, C vs. B, C vs. B, and C vs. A. This facilitates the determination of the comparator (e.g., control) group in each case, so as to calculate the study-specific *CER*. For example, in study 1 that compares B vs. A a *CER* is defined using evidence from treatment A. A *CER* is defined in a similar way in studies 2 to 6. Second, a *CER* should be defined across multiple treatment comparisons that share the same control (or comparator) group. This may include choosing between a common and comparison-specific *CER*. Selection of the most appropriate assumption will depend on the patient population. However, different assumptions may impact the NNT results. For example, for an $OR = 0.80$ a common *CER* across all treatments vs. control and equal to 0.50 gives a $NNT = 18$, whereas a comparison-specific

$CER = 0.05$ gives a notably different $NNT = 104$. In our fictional example in Appendix 1, a common CER across treatment comparisons sharing the same comparator group was assumed. Hence, the CER for treatment A for the treatment comparison B vs. A ($CER_{Bvs.A}^A$) is equal to the $CER_{Cvs.A}^A$. In particular, under the common CER assumption we need to estimate 2 CER s: $CER_{Bvs.A}^A = CER_{Cvs.A}^A$ and $CER_{Cvs.B}^B$. The CER for treatment A was estimated from studies 1, 2, 3 (comparing B vs. A treatments) and 6 (comparing C vs. A treatments), whereas the CER for treatment B was estimated from studies 1, 2, 3 (comparing B vs. A treatments), and 4 and 5 (comparing C vs. B treatments). However, under the comparison-specific assumption, we need to estimate 3 CER s: $CER_{Bvs.A}^A$, $CER_{Cvs.A}^A$, and $CER_{Cvs.B}^B$. In Appendix 1, we used approach 2 and calculated a mean CER across studies comparing the same control group.

Once a meaningful CER is calculated, the NNT can be determined using the formulae presented earlier. In Appendix 1, we present NNT using both the OR effect measure (NNT_{OR}) and the RD (NNT_{RD}) effect measure. To account for uncertainty around NNT , a CI can be calculated for the NNT values obtained in a NMA. Several approaches have been suggested to calculate CIs for NNT s for results from RCTs [8, 27], among which the Daly (or substitution method), the method of variance estimates recovery (MOVER), and the propagating imprecision (PropImp) CIs can also be used for results from meta-analyses [28-30]. For the NNT CI calculation, an appropriate method should be chosen to calculate CIs for the selected effect measure. For a review of methods to obtain CIs for the estimated overall effect from a random-effects meta-analysis see Veroniki et al. [31]. If the chosen effect measure is the RD, then the NNT CI is simply obtained by inverting and exchanging the corresponding RD confidence limits. If the chosen effect measure is the RR or OR, additionally a meaningful CER is required. The Daly CIs start

with a CI for the estimated overall treatment effect, and then calculate a CI based on a transformed scale. Although the method is simple to apply, it does not account for the estimation uncertainty of *CER*, when OR and RR effect sizes are used. On the contrary, the MOVER and PropImp approaches allow for a degree of imprecision of both treatment effect and *CER* estimation, and can be used when the estimates of *CER* and treatment effect are independent (e.g., derived from separate studies). This means that the average *CER* derived across the same eligible studies should not be used to calculate a MOVER or PropImp CI for NNT [32].

In NNT, values between -1 and 1 are impossible, and the domain of NNT uses two regions: a) the NNTB region, including the union of 1 (where is the largest possible beneficial treatment effect) to ∞ (no treatment effect), and b) the NNTH region: $-\infty$ (no treatment effect) to -1 (where is the largest possible harmful treatment effect). For example, a non-statistically significant $\text{NNT}=5$ with CI -40 and 2 is a combination of the two regions $(-\infty, -40]$ and $[2, \infty)$. The suggested presentation of a non-statistically significant NNT is: $\text{NNTB}=5$ (NNTH 40 to ∞ to NNTB 2) [4]. The presentation indicates that a $\text{NNTB}=5$ is estimated implying that on average 5 people should receive the treatment for an additional beneficial outcome compared to the control group. However, the uncertainty of this estimation is large with a harmful effect up to $\text{NNTH}=40$, a less harmful effect up to $\text{NNTH} = \infty$ (no effect; need to treat an infinite number of people to cause or avoid an event), and a more beneficial effect up to $\text{NNTB}=2$. Because of this limitation and the difficulty in interpreting a non-statistically significant NNT, many authors do not report a CI for non-statistically significant NNTs.

In Appendix 1 we present a 95% CI for each NNT using the Daly approach [30]. It should be highlighted that the resulting CIs for NNT_{OR} contain only the OR uncertainty

and do not account for *CER* uncertainty. Hence, the NNT estimation is conditional on the assumed *CER*. However, in case of large between-study heterogeneity, we recommend the use of various clinically meaningful *CER* values (e.g. for low- and high-risk patients) to explore differences in NNT. In case a *CER* estimate with CI is available, which is independent of the (network) meta-analysis, the PropImp approach can be used to calculate CIs for NNTs taking into account uncertainty of the *CER* and the OR estimation [29]. In Appendix 1, the NNT values slightly differ when calculated from OR and from RD. This is because different properties are associated with different effect measures, which can affect the NNT value. It should also be considered that small changes in RD close to zero may result in large changes in the estimation of NNT, as $RD = 0$ corresponds to $NNT = \pm\infty$

3. Illustrative Example

To illustrate different approaches for the graphical representation of NNT (see section 4) we use a published systematic review and NMA on the comparative effectiveness and safety of cognitive enhancers for treating Alzheimer's dementia [33]. The example includes eight dichotomous outcomes and 10 treatments. The network representation of each outcome is presented in Appendix 2. The treatment comparisons including placebo, the estimated ORs, RRs, and RDs in a frequentist NMA (using the *mvmeta* command in Stata) [34], the mean *CERs*, and the estimated NNTs for each outcome and effect measure are provided in Appendix 3. In this example, we used the OR, which was transformed to NNT for the graphical approaches in section 4. To ease interpretation in plots, we present the results on the RD scale after converting the transformed NNTs to RDs. For illustration purposes, we also present in Appendices 4-10 the same graphical approaches using the RD effect measure as estimated in NMA and its conversion to the NNT scale. However, it should be noted that the use of the RD effect measure is not appropriate in this example. Nevertheless, we used this approach here to illustrate the different graphs for RD-based NNTs without switching to another data example. We ordered treatments from oldest to newest by year of availability in Canada[33], used approach 2 and calculated a mean *CER* across studies comparing the control group, and considered a common *CER* value across treatment comparisons including the same, older treatment. Since the aim of this paper is to present different ways of depicting NNT, we used a single *CER* value to calculate NNT under the OR (and RR in Cates plot in Appendix 5) effect measure. We calculated a 95% CI for each NNT using the Daly approach [30]. In the following, we infer on whether a treatment is harmful or

beneficial based on the NNT scale, i.e. a treatment is harmful when NNTB ranges between 1 and ∞ , and a treatment is beneficial when NNTB ranges between 1 and ∞ .

4. Graphical approaches for NNT based on absolute measures

Several graphical ways can be used to present the NNT in a NMA. In this paper, we discuss six potential approaches to graphically represent NNT. We also categorize the plots when a single outcome or multiple outcomes are available in a NMA. The uncertainty around NNT can graphically be depicted in a bar plot and a forest plot. A scatterplot can also be extended to include CIs for NNTs as ellipse regions across treatment comparisons and outcomes [35]. For a comparison of the graphical approaches see Appendix 11.

4.1 Plots for a single outcome

4.1.1 Bar plot

A bar plot can graphically depict the NNT for each treatment comparison or the NNT for the treatments compared to a common comparator (e.g., placebo), as presented in Figure 1.

In Figure 1, we graphically represent the NNT values of 6 treatments for Alzheimer's dementia vs. placebo for the vomiting outcome [33] of 42 RCTs and 12,997 patients, in a bar plot. According to the NNT point estimates, all treatments but one are suggested as harmful treatments compared to placebo. The only beneficial treatment is memantine (NNTB=27, 95% CI [NNTB 3, ∞ , NNTB 15]), suggesting that 27 patients need to be treated with memantine compared to placebo to prevent one patient from vomiting. However, the point estimate is associated with large uncertainty, where its CI goes from large harm to large benefit. Donepezil, galamantine, and oral rivastigmine are statistically

significantly more harmful against placebo. The most harmful treatment among the 6 treatments evaluated in a NMA vs. placebo is oral rivastigmine (NNTH=7, 95% CI [5,14]), suggesting that 7 patients need to be treated with oral rivastigmine in order for one patient to vomit.

(Figure 1 here)

4.1.2 Cates plot

A Cates plot can be used to graphically present the NNT values derived from NMA evidence. The Cates plot shows the average rate of having a good outcome with treatment (green faces), a bad outcome with treatment (red faces), a better outcome with control (crossed green faces), and a change in outcome category if a patient is treated (yellow faces) per treatment comparison. 100 faces are depicted in a Cates plot representing patients treated with the underlying treatment. The more green faces in a section referring to a certain treatment comparison indicate the most beneficial the treatment against its comparator, whereas the more red faces in a section referring to a certain treatment comparison indicate the most harmful the treatment against its comparator.

Assuming a common *CER* across comparisons with mean *CER* = 7% across studies, we plotted a Cates plot for each treatment against placebo at <http://www.nntonline.net/visualrx/>. Figure 2 demonstrates the Cates plot for the vomiting outcome and 6 treatments against placebo: donepezil, galantamine, oral rivastigmine, transdermal patch rivastigmine, memantine, and rivastigmine + memantine. This plot suggests that the most beneficial treatment is memantine, where 93 patients treated with memantine had a good outcome of not vomiting, 4 patients, who would vomit without memantine, had a change in outcome and did not vomit after receiving treatment, and 3 patients had a bad outcome of vomiting even if they were treated with memantine

(NNTB=27, 95% CI [NNTB 3, ∞ , NNTB 15]). The least harmful treatment is transdermal patch rivastigmine, where 38 patients need to be treated with transdermal patch rivastigmine in order for one patient to vomit (NNTB=37, 95% CI [NNTB 8, ∞ , NNTB 39]). The Cates plot suggests that 90 patients treated with transdermal patch rivastigmine had a good outcome of not vomiting, 3 patients had an adverse event with transdermal patch rivastigmine and their category from a good outcome changed to a bad outcome of vomiting, and 7 patients had a bad outcome of vomiting even if they were treated with transdermal patch rivastigmine.

(Figure 2 here)

4.1.3 Forest plot

A forest plot can graphically depict the estimated NNT for each treatment comparison. On the x-axis the $RD \times 100\%$ scale is shown with 0% corresponding to the line of no treatment difference, and on the y-axis the treatment comparisons are presented. The NNT values along with their CIs are depicted on the left hand-side of the plot next to the RD values. In the forest plot, each treatment comparison is presented by a diamond on the $RD \times 100\%$ scale and a horizontal line extending either side of the diamond depicts a CI for $RD \times 100\%$. The treatment comparisons may be divided into subsets for presentation in a forest plot, such as according to the common comparator in the NMA treatment comparisons.

The forest plot of 6 treatments against placebo assessed for vomiting in a NMA of patients with Alzheimer's dementia is shown in Figure 3. This plot shows that donepezil, galantamine, and oral rivastigmine are statistically significantly harmful when compared with placebo, and among the three treatments the highest uncertainty around NNT is observed for donepezil (NNTB=22, 95% CI [10,113]). Memantine, transdermal patch

rivastigmine, and rivastigmine + memantine are associated with non-statistically significant NNTs and very wide 95% CIs.

(Figure 3 here)

4.2 Plots for multiple outcomes

4.2.1 Bubble plot

A bubble plot shows the NNT values for all treatment comparisons assessed in a NMA for two outcomes. The plot arranges the presentation of NNT for all treatments on a certain outcome on the x-axis against the treatments included in a second outcome on the y-axis. Let us define that the outcome presented at the lower diagonal part of the plot is outcome 1 (e.g., headache in Figure 4) and the outcome presented at the upper diagonal part of the plot is outcome 2 (e.g., nausea in Figure 4). The direction of the treatment comparisons in outcome 1 (e.g., headache) is defined as treatment at the relevant row (e.g., donepezil) vs. treatment at the relevant column (e.g., placebo). Similarly, the direction of the treatment comparisons in outcome 2 (e.g., nausea) is defined as treatment at the relevant row (e.g., placebo) vs. treatment at the relevant column (e.g., donepezil). The diagonal of the plot gives no information about NNT. The area in each circle is proportional to the absolute $RD \times 100\%$, and the number in each circle represents the NNT value for the corresponding treatment against the comparator for the specific outcome. However, a challenge with bubble plots is that the smaller the circle, the harder it is to read the NNT value. Each point corresponds to four pieces of information: treatment comparison, magnitude of RD, benefit/harm of treatment, and NNT value. Green circles represent the number of patients need to be treated to prevent one patient from having an

event, whereas red circles show the number of patients need to be treated in order for one patient to experience a harmful event.

Figure 4 demonstrates the bubble plot for the NNT of 8 NMA treatments included in headache (x-axis) and nausea (y-axis) outcomes. In this plot, the NNT values for all NMA treatment comparisons are presented according to headache (lower diagonal) and nausea (upper diagonal) outcomes. For example, for the headache outcome, the comparison row treatment vs. column treatment donepezil vs. placebo has a NNTH=73, whereas in nausea the comparison row treatment vs. column treatment placebo vs. donepezil has a NNTB=17 (equivalent to donepezil vs. placebo: NNTH=17). The plot suggests that the most beneficial treatment for nausea is donepezil + memantine against placebo (donepezil + memantine vs. placebo: NNTB=17), but the same treatment is the most harmful treatment for headache against placebo (donepezil + memantine vs. placebo: NNTH=7). The only beneficial treatment against placebo in headache is rivastigmine + memantine, which is also beneficial in nausea (rivastigmine + memantine vs. placebo, headache: NNTB=33, nausea: NNTB=55). The least beneficial treatment in nausea is transdermal patch rivastigmine, which is one of the most harmful treatments against placebo in headache (transdermal patch rivastigmine vs. placebo, headache: NNTH=17, nausea: NNTB=117).

(Figure 4 here)

4.2.2 Scatterplot

For the case of two outcomes, two-dimensional scatterplots can be used, which can be extended to the case of three outcomes with three-dimensional plots. The plot presents both the $RD \times 100\%$ and NNT values for treatments against a common comparator across

two (or a maximum of three) outcomes. Clustering methods can be used to group the NNT performance of treatments according to their efficacy and/or safety [36].

Figure 5 depicts the $RD \times 100\%$ values of 7 treatments against placebo for headache and nausea in a scatterplot. The NNT scale is presented on the right and upper scales of the plot. The plot suggests that the only beneficial treatment vs. placebo in both outcomes is rivastigmine + memantine (headache: NNTB=33, nausea: NNTB=55). The least beneficial treatment in nausea is transdermal patch rivastigmine against placebo (NNTB=117), whereas the only beneficial treatment in headache is rivastigmine + memantine. The most harmful treatment in the headache outcome is donepezil + memantine vs. placebo (NNTH=7), but the same treatment is the most beneficial treatment in the nausea outcome vs. placebo (NNTB=17).

(Figure 5 here)

4.2.3 Rank-heat plot

The rank-heat plot can be used for the visual presentation of the NNT values across multiple treatments and outcomes [37]. A rank-heat plot includes N circles with the same center corresponding to the N outcomes assessed in a NMA. The radii included in each concentric circle correspond to T treatment comparisons as assessed in NMA. Instead of presenting all available treatment comparisons, one can present the NMA treatments against a common comparator (e.g., placebo). Each section in the rank-heat plot is colored according to the NNT value of the particular treatment at the corresponding outcome. The NNT scale ranges from NNTH=1 to ∞ to NNTB=1 and is transformed using three colors: red (NNTH=1) yellow (NNTH/NNTB= ∞) and green (NNTB=1). Although the color of the section is interpretable, the section area does not convey any information. Statistically significant NNT results are depicted in the rank-heat plot by highlighting the borders in the

corresponding section. Uncolored sections refer to NMA treatments without data on the outcome within the circle. A star symbol can be used to highlight these cases (see <https://rh.ktss.ca/site/nnt>).

Figure 6 displays the hierarchy of 10 treatments for Alzheimer's dementia against placebo across 8 outcomes according to their NNT values in a rank-heat plot. The NNT scale is presented at the top of the graph. The plot suggests that donepezil + memantine lies among the most beneficial treatments when compared with placebo across most outcomes except for headache with NNTH=7. However, due to lack of evidence we cannot infer the treatment's harm or benefit in bradycardia and diarrhea outcomes. Across all outcomes and treatment comparisons, 10 NNTs are statistically significant and these refer to donepezil, galamantine, and oral rivastigmine treatments.

(Figure 6 here)

All plots can present NNTs from NMA, but the bar plot, Cates plot, and forest plot can be cumbersome when a large number of NNTs is available, especially when more than one outcome is available. An NNT can be particularly helpful when different outcomes with widely different *CER* values (e.g., harmful and beneficial outcomes) are compared, to reflect the different likelihood of each outcome. Similarly, an NNT is helpful for comparing different interventions. A disadvantage of the bubble plot is that the smaller the circle the harder it is to read the NNT value, whereas a scatterplot cannot be produced when different treatments (or treatment comparisons) are included in the studied outcomes. A challenge associated with the Cates plot, bubble plot, and rank-heat plot is that they do not depict the NNT uncertainty, which can impact interpretation. Although the interpretation of non-statistically significant NNTs is challenging, when we only consider a NNT point estimate or direction of effect that shows benefit (or harm) and do not account

for the huge estimation uncertainty (CI is going from large harm to large benefit), our conclusions can be misleading. For example, based on the NNT point estimate rivastigmine + memantine is suggested as a beneficial treatment when compared to placebo in both headache and nausea outcomes (headache: NNTB=33, nausea: NNTB=55). Interpreting only the point estimates rather than the combination of point estimates and uncertainty around them can lead to an erroneous decision making considering also that nausea and headache are adverse events related to these medications (headache: NNTB 33 (NNTH 2, ∞ , NNTB 13), nausea: NNTB 55 (NNTH 7, ∞ , NNTB 15)). The Forest plot on the RD scale is probably one of the easiest ways to present uncertainty around each result, followed by the bar plot.

5. Discussion

We recommend the presentation of NNT along with the relevant effect measure and its CI when it is useful to describe the treatment effects in an absolute scale. The NNT values can be presented for all available or selected treatment comparisons (e.g., active treatments vs. placebo) from a NMA. We suggest the presentation of all results using the main effect measure used in the analysis (e.g., OR), and of selected, interesting for the considered research question, results using NNT. An important consideration when calculating NNT, is that it may vary according to the effect measure used in meta-analysis or NMA. Therefore, it is important to choose the appropriate main effect measure in meta-analysis or NMA before NNTs are calculated.

When the OR or RR effect measures are used in meta-analysis or NMA, a useful *CER* should be assumed to estimate NNT. As discussed in section 2, several ways exist to select a *CER* value for the NNT calculation, including mean *CER* across studies, pooled

CER in meta-analysis, expert opinion-based *CER*, and range of possible *CERs*. In the presence of small to moderate heterogeneity, we suggest the use of several *CER* values (e.g. for low- and high-risk patients) to estimate a NNT and assess robustness of results. By means of these assumed *CERs* we can calculate NNTs and their CIs (e.g., based upon the Daly approach [30], but this neglects the estimation uncertainty of *CER*). In case external estimation of *CER* is available (e.g., from registry data), which is independent on the data used in the underlying meta-analysis or NMA, and in case the RR is the main effect measure, we can use the MOVER approach to estimate NNT and its CI taking into account the *CER* estimation uncertainty [28]. In case the OR is the main effect measure, the PropImp approach can be used [29]. In NMA, additional considerations are required to calculate NNTs, which include a meaningful and consistent order of treatments to facilitate the *CER* choice for NNT calculation and interpretation, and a selection among different *CER* assumptions (i.e., common or comparison-specific *CER*). Since NNT is dependent on *CER* and study duration, the comparison of multiple treatments for a specific outcome through NNT may be difficult. The selection among different *CER* assumptions depends on the clinical field and the nature of the treatments assessed in an NMA. If different *CER* values (e.g., derived from control arms of the included studies) influence the NNT calculation, then this should be considered when interpreting the NNT. We suggest that NNTs always be interpreted along with the relevant treatment effects and their confidence intervals estimated in a meta-analysis or NMA. Ranking statistics derived from an NMA model can also be used as complementary information to NNTs to compare treatments within each outcome of interest [38].

In this paper, we discussed the NNT calculation for dichotomous data. However, the estimation of NNT can also be helpful for continuous outcomes. A way to calculate

406 NNT for continuous data can be by converting a standardized mean difference to OR and
407 then calculate NNT [5] or by dichotomizing the continuous data and then calculate an
408 effect size for dichotomous data. In any case, we suggest to graphically represent NNT to
409 ease interpretation. However, it should be considered that the NNT interpretation may
410 differ according to the NMA considerations, including selection of effect size and *CER*, as
411 well as *CER* assumption across multiple comparisons.

Declarations**List of Abbreviations**

CER, control event rate

CI, confidence interval

MOVER, method of variance estimates recovery

NMA, network meta-analysis

NNH, number needed to harm

NNT, number needed to treat

NNTB, number needed to treat for an additional beneficial outcome

NNTH, number needed to treat for an additional harmful outcome

OR, odds ratio

PropImp, propagating imprecision

RD, risk difference

RR, risk ratio

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Submission Declaration and verification

This article has not been published previously

Availability of data and materials

The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.

Funding

SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation. ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.

Authors' contributions

AAV, RB, PG, SES and ACT conceived and designed the study. AAV conducted the analysis. AAV wrote the first draft manuscript and the other authors edited the manuscript.

Acknowledgements

We would like to thank Alexandros Fyraridis, Andrea Jimenez, and Megan Mak for building the rank-heat plot web-tool (<https://rh.ktss.ca/site/nnt>). We thank Shazia Siddiqui, Myanca Rodrigues, Krystle Amog and Sinit Michael for helping format the manuscript.

Reference List

- [1] Bender R. Number Needed to Treat: Overview. In: Balakrishnan N, Brandimarte P, Everitt BS, Molenberghs G, Ruggeri F, Piegorsch W, Eds., editors. Wiley StatsRef: Statistics Reference Online: John Wiley & Sons, Ltd; 2017.
- [2] Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. *N Engl J Med*. 1988;318:1728-33.
- [3] McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. *Ann Intern Med*. 1997;126:712-20.
- [4] Altman DG. Confidence intervals for the number needed to treat. *BMJ*. 1998;317:1309-12.
- [5] Higgins JPT, Green S. (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. 2011; Available from: <http://handbook.cochrane.org>.
- [6] Stang A, Poole C, Bender R. Common problems related to the use of number needed to treat. *J Clin Epidemiol*. 2010;63:820-5.
- [7] Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT)--needs treatment with care. *Basic Clin Pharmacol Toxicol*. 2006;99:12-6.
- [8] Bender R. Calculating confidence intervals for the number needed to treat. *Control Clin Trials*. 2001;22:102-10.
- [9] Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. *Int J Epidemiol*. 2002;31:72-6.
- [10] Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. *BMJ*. 1999;319:1492-5.
- [11] Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ*. 1995;310:452-4.
- [12] Sackett DL. On some clinically useful measures of the effects of treatment. *Evid Based Med*. 1996;1:37-8.
- [13] Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. *JAMA*. 2002;287:2813-4.
- [14] da Costa BR, Rutjes AW, Johnston BC, Reichenbach S, Nuesch E, Tonia T, et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. *Int J Epidemiol*. 2012;41:1445-59.
- [15] Furukawa TA, Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. *PLoS One*. 2011;6:e19070.
- [16] Lesaffre E, Boon P, Pledger GW. The value of the number-needed-to-treat method in antiepileptic drug trials. *Epilepsia*. 2000;41:440-6.
- [17] Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. *BMJ*. 2002;324:827-30.
- [18] Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ*. 2005;331:897-900.
- [19] Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat Med*. 1996;15:2733-49.
- [20] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med*. 2004;23:3105-24.
- [21] Petropoulou M, Nikolakopoulou A, Veroniki AA, Rios P, Vafaei A, Zarin W, et al. Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. *J Clin Epidemiol*. 2017;82:20-8.
- [22] Zarin W, Veroniki AA, Nincic V, Vafaei A, Reynen E, Motiwala SS, et al. Characteristics and knowledge synthesis approach for 456 network meta-analyses: a scoping review. *BMC Med*. 2017;15:3.
- [23] Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health*. 2013;67:974-8.
- [24] Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Stat*. 1950;21:607-11.
- [25] Miller JJ. The inverse of the Freeman-Tukey double arcsine transformation. *Am Stat*. 1978;32:138.
- [26] Schwarzer G, Rücker G. Freeman-Tukey Double Arcsine Transformation in Meta-Analysis of Single Proportions. *Biometrisches Kolloquium Biometrie: Gelebte Vielfalt*. University of Frankfurt 2018.
- [27] Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. *Stat Med*. 1998;17:873-90.

- [28] Newcombe RG. MOVER-R confidence intervals for ratios and products of two independently estimated quantities. *Stat Methods Med Res.* 2016;25:1774-8.
- [29] Newcombe RG. Propagating imprecision: combining confidence intervals from independent sources. *Communications in Statistics-Theory and Methods.* 2011;40:3154-80.
- [30] Daly LE. Confidence limits made easy: interval estimation using a substitution method. *Am J Epidemiol.* 1998;147:783-90.
- [31] Veroniki A, Jackson D, Bender R, Kuss O, Langan D, Higgins J, et al. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. *Research synthesis methods.* 2018 Under Review.
- [32] Newcombe RG, Bender R. Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk. *Evid Based Med.* 2014;19:6-8.
- [33] Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, et al. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. *J Am Geriatr Soc.* 2017;doi: 10.1111/jgs.15069.
- [34] White IR. Multivariate random-effects meta-analysis. *Stata Journal.* 2009;9:40-56.
- [35] Riley RD, Price MJ, Jackson D, Wardle M, Gueyffier F, Wang J, et al. Multivariate meta-analysis using individual participant data. *Research synthesis methods.* 2015;6:157-74.
- [36] Romesburg HC. Cluster analysis for researchers. Learning Publications. 1985.
- [37] Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. *J Clin Epidemiol.* 2016;76:193-9.
- [38] Veroniki AA, Straus SE, Rucker G, Tricco AC. Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis? *J Clin Epidemiol.* 2018;100:122-9.

Figure Legend

Figure 1. Bar plot of 6 treatments against placebo for the vomiting outcome. On the x-axis, the treatment comparisons are presented, and on the y-axis, the $RD \times 100\%$ scale is shown, whereas the NNT values along with their CIs are depicted at the top of each bar. Each vertical bar depicts the $RD \times 100\%$ value that corresponds to the specific treatment comparison, and each vertical line crossing a bar correspond to the error bars depicting the 95% CI for $RD \times 100\%$. Error bars crossing the line of no effect ($RD \times 100\% = 0\%$) suggest a non-statistically significant result. The greater the area in a bar, the larger the absolute RD, i.e., the smaller the NNTB (or NNTH) value, and hence the most beneficial (or harmful) the treatment. We can distinguish between harmful (below the horizontal line of no effect) and beneficial (above the horizontal line of no effect) treatments using red and green colored bars, respectively. On the horizontal axis the 6 treatment comparisons are presented, whereas on the vertical axis the $RD \times 100\%$ value of each treatment comparison is presented. Each bar represents one of the 6 (i.e., total number of treatments in vomiting outcome-1) possible comparisons against a common comparator (i.e., placebo). The error bars represent the 95% CI for NNT. Green bars represent the number of patients need to be treated to prevent one patient from experiencing the event; red bars represent the number of patients need to be treated in order for one patient to experience the event. Although the NNT scale suggests that memantine is the only beneficial treatment compared to its alternatives in the network, given that memantine does not treat vomiting clinically memantine would be described as the least harmful treatment.

Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, memantine; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine.

Figure 2. Cates plot representing 6 treatments against placebo in the vomiting network. Each region corresponds to a different treatment (vs. placebo) and includes 100 faces corresponding to the patients treated with the underlying treatment. Green faces represent patients not vomiting with the underlying treatment; red faces represent patients vomiting with the underlying treatment; crossed green faces represent patients not vomiting with control; yellow faces represent patients that would not vomit if they would be treated with the underlying treatment. The NNT values have been re-calculated in <http://www.nntonline.net/visualrx/> using the odds ratios estimated in a NMA model and a mean CER=7%. Although the NNT scale suggests that memantine is the only beneficial treatment compared to its alternatives in the network, given that memantine does not treat vomiting clinically memantine would be described as the least harmful treatment.

Abbreviations: CER, control event rate; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome.

Figure 3. Forest plot for 6 NMA treatment comparisons against placebo to assess vomiting in Alzheimer's dementia. The $RD \times 100\%$, its 95% CI, the corresponding NNT and its 95% CI for each comparison are shown. Note that the pooled or effect measure estimated in NMA has been transformed to NNT, and the NNT has been converted to an RD effect measure, which is presented in this plot.

Abbreviations: CI, confidence interval; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RD, risk difference.

Figure 4. Bubble plot for the 8 NMA treatments (including placebo) included in headache (x-axis) and nausea (y-axis) outcomes. The NNT values for each pair of the Alzheimer's dementia treatments according to headache (lower diagonal) and nausea (upper diagonal) are presented. The area of each circle is proportional to the $RD \times 100\%$ value of each treatment comparison, and the NNT value is presented in the center of each circle. Green circles represent the number of patients need to be treated to prevent one patient from experiencing the event; red circles represent the number of patients need to be treated in order for one patient to experience the event. The direction of the treatment comparisons is defined as row treatment vs. column treatment. Although the NNT scale suggests that there are beneficial treatments in the network, given that

these treatments do not treat nausea or headache clinically they would be described as the less harmful treatments.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; PLAC, placebo; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine.

Figure 5. Scatterplot for the NNT of 7 treatments vs. placebo for headache (x-axis) and nausea (y-axis) outcomes for patients with Alzheimer's dementia. Treatments lying on the upper right hand side quarter are more beneficial against placebo for both outcomes. Although the NNT scale suggests that there are beneficial treatments in the network, given that these treatments do not treat nausea or headache clinically they would be described as the less harmful treatments.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNT, number needed to treat; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine.

Figure 6. Rank-heat plot of the NNT values of 8 treatments in 8 different outcomes. Each section is colored according to the NNT value of the corresponding treatment and outcome. The scale consists of the transformation of three colors red (NNTH=1), yellow (∞), and green (NNTB=1). Each section includes also the NNT value corresponding to the specific treatment and outcome. Highlighted borders in a section correspond to statistically significant NNT results. Uncolored sections show that the underlying treatment was not included in the NMA for the particular outcome. Although the NNT scale suggests that there are beneficial treatments in the network, given that these treatments do not treat nausea or headache clinically they would be described as the less harmful treatments.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine; SAE, serious adverse events.

Additional Files

File name: Supplementary File

Appendix 1: Table for fictional example for the calculation of NNT in NMA.

Fictional example for the calculation of NNT in NMA. For each treatment comparison a pooled OR and a pooled RD was calculated in a random-effects NMA model using the mvmeta command in Stata [34]. A study-specific CER was calculated for treat2 (even if this was not the reference/control group) across treatment comparisons. A common CER across treatment comparisons sharing the same comparator (e.g., control) group was assumed. The CER for treatment A was estimated from studies 1, 2, 3, and 6; the CER for treatment B was estimated from studies 1, 2, 3, 4, and 5. A mean CER was calculated across studies, and a 95% CI for NNT across treatment comparisons was calculated using the Daly approach.

Abbreviations: CER, control event rate; CI, confidence interval; Comp, comparison; N, sample size; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; OR, odds ratio; RD, risk difference; Treat, treatment

Appendix 2: Network representation of eight outcomes included in the illustrative example [33]

Each treatment node is proportional to the number of patients in the particular treatment, and each edge is proportional to the number of studies comparing the treatments it connects.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; PLAC, placebo; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal rivastigmine; SAE, serious adverse events

Appendix 3. NNT values across all treatments vs. placebo in 8 Alzheimer's dementia outcomes.

Treatment comparisons including placebo, estimated odds ratios (ORs), risk ratios (RRs), and risk differences (RDs), mean control event rates (CER), and estimated number needed to treat (NNT) for each outcome in the Alzheimer's dementia dataset [33] and effect measure. All effect measures were calculated in a frequentist network meta-analysis using the mvmeta Stata [34] routine.

Abbreviations: CER, control event rate; CI, confidence interval; CrI, credible interval; DONE, donepezil; GALA, galantamine; MEMA, memantine; N, sample size; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; OR, odds ratio; PLAC, placebo; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine; RR, risk ratio; Treat, treatment; SAE, serious adverse events

Appendix 4. Bar plot of NNT values across 6 treatments vs. placebo in vomiting outcome.

Bar plot of 6 treatments against placebo for the vomiting outcome. On the horizontal axis the 6 treatment comparisons are presented, whereas on the vertical axis the $RD \times 100\%$ value of each treatment comparison is presented. Each bar represents one of the 6 (i.e., total number of treatments in vomiting outcome-1) possible comparisons against a common comparator (i.e., placebo). The error bars represent the 95% CI for NNT. Green bars represent the number of patients need to be treated to prevent one patient from experiencing the event; red bars represent the number of patients need to be treated in order for one patient to experience the event. NNT values have been calculated from pooled RD effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the outcome is harmful.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 5. Cates plot of NNT values across 6 treatments vs. placebo in vomiting outcome.

Cates plot representing 6 treatments against placebo in the vomiting network. Each region corresponds to a different treatment (vs. placebo) and includes 100 faces corresponding to the patients treated with the underlying treatment. Green faces represent patients not vomiting with the underlying treatment; red faces represent patients vomiting with the underlying treatment; crossed green faces represent patients not vomiting with control; yellow faces represent patients that would not vomit if they would be treated with the underlying treatment. The NNT values have been re-calculated in <http://www.nntonline.net/visualrx/> using the risk ratios estimated in a NMA model and a mean CER=6.92%.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 6. Forest plot of NNT values across 6 treatments vs. placebo in vomiting outcome.

Forest plot for 6 NMA treatment comparisons against placebo to assess vomiting in Alzheimer's dementia. The $RD \times 100\%$, its 95% CI, the corresponding NNT and its 95% CI for each comparison are shown. NNT values have been calculated from pooled RD effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the outcome is harmful.

Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 7. Bubble plot of NNT values across all treatment comparisons among 8 treatments (including placebo) assessed in headache and nausea outcomes.

Bubble plot of NNT values across all treatment comparisons among 8 treatments (including placebo) assessed in headache (x-axis) and nausea (y-axis) outcomes. The NNT

values for each pair of the Alzheimer's dementia treatments according to headache (lower diagonal) and nausea (upper diagonal) are presented. The area of each circle is proportional to the $RD \times 100\%$ value of each treatment comparison, and the NNT value is presented in the centre of each circle. Green circles represent the number of patients need to be treated to prevent one patient from experiencing the event; red circles represent the number of patients need to be treated in order for one patient to experience the event. The direction of the treatment comparisons is defined as row treatment vs. column treatment. NNT values have been calculated from pooled RD effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the outcomes are harmful.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 8. Scatterplot of NNT values across 7 treatments vs. placebo in headache and nausea outcomes.

Scatterplot for the NNT of 7 treatments vs. placebo for headache (x-axis) and nausea (y-axis) outcomes for patients with Alzheimer's dementia. Treatments lying on the upper right-hand side quarter are more harmful against placebo for both outcomes. In this example all treatments lie on the upper right hand side quarter, since all are more harmful than placebo. NNT values have been calculated from pooled RD effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the outcomes are harmful.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 9. Rank-heat plot of NNT values across all treatment comparisons among 8 treatments (including placebo) assessed in 8 Alzheimer's dementia outcomes.

Rank-heat plot of the NNT values across all treatment comparisons among 8 treatments (including placebo) assessed in 8 different outcomes. Each section is coloured according to the NNT value of the corresponding treatment and outcome. The scale consists of the transformation of three colours red (NNTH=1), yellow (∞), and green (NNTB=1). Each section includes also the NNT value corresponding to the specific treatment and outcome. Highlighted borders in a section correspond to statistically significant NNT results. Uncoloured sections show that the underlying treatment was not included in the NMA for the particular outcome. NNT values have been calculated from pooled RD effect sizes estimated in NMA.

Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; PLAC, placebo; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine; SAE, serious adverse events

Appendix 10. Interval plot of NNT values across 6 treatments vs. placebo in vomiting outcome.

Interval plot for 6 NMA treatment comparisons against placebo to assess vomiting in Alzheimer's dementia. The x-axis represents the treatment comparisons and the y-axis depicts the $RD \times 100\%$ scale. The $RD \times 100\%$, its 95% CI, the corresponding NNT and its 95% CI for each comparison are shown. NNT values have been calculated from pooled RD

effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the outcome is harmful.

Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine

Appendix 11: Overview of the properties of the graphical tools presenting the number needed to treat (NNT).

The characteristics have been categorized to No [--], Yes [✓], Maybe [(✓)].

As shown here, the NNT results can be displayed in several graphs, each of which serves different needs and has different properties. A comparison of the plots according to their properties is shown in Appendix 11. The NNT results from a single outcome can be presented in a bar plot, Cates plot or forest plot. An advantage of both the bar plot and forest plot is that they can be used to graphically represent the NNT uncertainty. The Cates plot can be recommended to illustrate the meaning of NNT estimates to knowledge users. However, the Cates plot is only useful if the effect estimates are statistically significant and the estimation uncertainty is not too large. Altman [4] suggested a different version of the forest plot presented in this paper, where the NNT values and their CIs are plotted instead of the main effect measure values. Another similar plot to the forest plot is the interval plot, where the x-axis represents the treatment comparisons and the y-axis depicts the effect measure (e.g., RD scale; see Appendix 11). When two outcomes are of interest, the bubble plot and scatterplot can be used, where we can assess whether a treatment is beneficial in one outcome compared to a certain comparator, and whether it is also beneficial or harmful in another outcome when compared to the same comparator. When two or more outcomes are available, a rank-heat plot can be considered, which offers the opportunity of comparing the results across a variety of treatment comparisons.

Vomiting Outcome

What is new?**Key Findings:**

- The number needed to treat (NNT) is an absolute measure of effect used to communicate the effectiveness or safety of an intervention and is frequently used in the meta-analytical literature.

What this adds to what is known:

- Different considerations of calculating a NNT in both pairwise and network meta-analysis (NMA), including effect size and assumptions for the control event rate across multiple comparisons, may impact NNT results. We present potential ways of calculating NNT in (network) meta-analysis, such as mean control event rate (*CER*) across studies, pooled *CER* in meta-analysis, expert opinion-based *CER*, and range of possible *CERs*.

What is the implication?

- The graphical representation of NNTs from NMA is crucial to ease interpretation of results. We present six graphical approaches for NNT from NMA and discuss their properties. We suggest the NNT graphical representation in a bar plot, Cates plot or forest plot for a single outcome, and in a bubble plot, scatterplot or rank-heat plot for at least two outcomes.

What should change now?

- Different plots can be used for different needs. For example, if uncertainty around NNT should be considered in decision-making, then a bar plot or a forest plot can be used. When multiple outcomes need to be considered, then a rank-heat plot is suggested. For communication purposes the Cates plot is suggested if the corresponding effect estimate is statistically significant and the confidence interval is not too wide.

ACCEPTED MANUSCRIPT

Declaration of Interest

Drs. Tricco A.C. and Straus S.E. are on the editorial board of the Journal of Clinical Epidemiology, but were not involved with the peer review process or decision for publication and not involved in any way in the journal management of this manuscript. The other authors have nothing to declare.